| Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED) (NCT00423150) | Merck Sharp & Dohme LLC | 2007-01-26 |
| Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) (NCT00432042) | Merck Sharp & Dohme LLC | 2007-01-12 |
| Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Cough From an Unknown Cause (Study P04888) (NCT00506545) | Merck Sharp & Dohme LLC | 2007-01-01 |
| A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED) (NCT00411554) | Merck Sharp & Dohme LLC | 2007-01-01 |
| A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066) (NCT00424775) | Merck Sharp & Dohme LLC | 2007-01-01 |
| Study of the Efficacy and Safety of SCH 486757 in Subjects With Chronic Cough (Study P04887) (NCT00506987) | Merck Sharp & Dohme LLC | 2007-01-01 |
| Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523) (NCT00423670) | Merck Sharp & Dohme LLC | 2007-01-01 |
| Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED) (NCT00337727) | Merck Sharp & Dohme LLC | 2007-01-01 |
| Initial Combination With Pioglitazone Study (0431-064) (NCT00397631) | Merck Sharp & Dohme LLC | 2006-12-19 |
| V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028) (NCT00411749) | Merck Sharp & Dohme LLC | 2006-12-11 |
| Sitagliptin Added-on to Insulin Study (0431-051) (NCT00395343) | Merck Sharp & Dohme LLC | 2006-12-11 |
| Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706) (NCT00482612) | Merck Sharp & Dohme LLC | 2006-12-07 |
| Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028) (NCT00559468) | Merck Sharp & Dohme LLC | 2006-12-07 |
| Fifty Two Week Extension Trial of Org 50081 (Esmirtazapine) in the Treatment of Insomnia (P05708) (NCT00610675) | Merck Sharp & Dohme LLC | 2006-12-07 |
| Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED) (NCT00441012) | Merck Sharp & Dohme LLC | 2006-12-01 |
| Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016) (NCT00684203) | Merck Sharp & Dohme LLC | 2006-12-01 |
| Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773) (NCT00686881) | Merck Sharp & Dohme LLC | 2006-12-01 |
| Exercise Study in Patient With Chronic Obstructive Pulmonary Disease (0000-036) (NCT00387036) | Merck Sharp & Dohme LLC | 2006-12-01 |
| A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis (NCT00407927) | Merck Sharp & Dohme LLC | 2006-12-01 |
| Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012) (NCT00441701) | Merck Sharp & Dohme LLC | 2006-12-01 |
| Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060) (NCT00440297) | Merck Sharp & Dohme LLC | 2006-12-01 |
| Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED) (NCT00423800) | Merck Sharp & Dohme LLC | 2006-12-01 |
| A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008) (NCT00405054) | Merck Sharp & Dohme LLC | 2006-12-01 |
| Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001) (NCT00359671) | Merck Sharp & Dohme LLC | 2006-12-01 |
| Dyskinesia in Parkinson's Disease (Study P04501) (NCT00406029) | Merck Sharp & Dohme LLC | 2006-11-20 |
| A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED) (NCT00399802) | Merck Sharp & Dohme LLC | 2006-11-16 |
| A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED) (NCT00736333) | Merck Sharp & Dohme LLC | 2006-11-01 |
| Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED) (NCT00440531) | Merck Sharp & Dohme LLC | 2006-11-01 |
| MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED) (NCT00362024) | Merck Sharp & Dohme LLC | 2006-11-01 |
| MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011) (NCT00420420) | Merck Sharp & Dohme LLC | 2006-11-01 |
| The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)(COMPLETED) (NCT00421278) | Merck Sharp & Dohme LLC | 2006-11-01 |
| A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092) (NCT00445094) | Merck Sharp & Dohme LLC | 2006-11-01 |
| An Investigational Drug Study to Assess Weight Loss in Patients With Type 2 Diabetes Mellitus (0364-011)(TERMINATED) (NCT00430742) | Merck Sharp & Dohme LLC | 2006-11-01 |
| Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630) (NCT00871910) | Merck Sharp & Dohme LLC | 2006-10-11 |
| Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594) (NCT00687011) | Merck Sharp & Dohme LLC | 2006-10-10 |
| ProQuad® Intramuscular vs Subcutaneous (NCT00402831) | Merck Sharp & Dohme LLC | 2006-10-06 |
| A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057) (NCT00414050) | Merck Sharp & Dohme LLC | 2006-10-06 |
| Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003) (NCT00365443) | Merck Sharp & Dohme LLC | 2006-10-01 |
| Five-Year Observation of Remicade Treatment for Plaque Psoriasis in Austria (Study P04900) (NCT00725452) | Merck Sharp & Dohme LLC | 2006-10-01 |
| Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED) (NCT00350623) | Merck Sharp & Dohme LLC | 2006-10-01 |
| A Weight Maintenance Study in Obese Patients (0364-012)(TERMINATED) (NCT00420589) | Merck Sharp & Dohme LLC | 2006-10-01 |
| A 52-Week Study to Assess the Effects of MK0822 on Knee Osteoarthritis (MK-0822-011) (NCT00397683) | Merck Sharp & Dohme LLC | 2006-10-01 |
| A Study to Evaluate the Safety and Efficacy of an Investigational Drug in the Treatment of Postoperative Dental Pain (MK-2295-005) (NCT00387140) | Merck Sharp & Dohme LLC | 2006-10-01 |
| A Study of a Bivalent Influenza Peptide Conjugate Vaccine in Healthy Adults (NCT00851266) | Merck Sharp & Dohme LLC | 2006-10-01 |
| An Investigational Drug Study to Assess Weight Loss in Obese and Overweight Patients (0364-037)(TERMINATED) (NCT00384605) | Merck Sharp & Dohme LLC | 2006-10-01 |
| MK0524A Bioequivalence Study (0524A-059) (NCT00944645) | Merck Sharp & Dohme LLC | 2006-10-01 |
| Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin (NCT00395421) | Merck Sharp & Dohme LLC | 2006-10-01 |
| Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed) (NCT00424554) | Merck Sharp & Dohme LLC | 2006-09-26 |
| Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017) (NCT00684515) | Merck Sharp & Dohme LLC | 2006-09-21 |
| Assessment of the Social Cost of Crohn's Disease: Economic and Quality of Life Aspects (Study P04560) (NCT00723840) | Merck Sharp & Dohme LLC | 2006-09-01 |
| Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062) (NCT00705198) | Merck Sharp & Dohme LLC | 2006-09-01 |
| A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816) (NCT00536588) | Merck Sharp & Dohme LLC | 2006-09-01 |
| The Canadian Follow-up Program for the ATTRACT Study (P04868)(TERMINATED) (NCT00748930) | Merck Sharp & Dohme LLC | 2006-09-01 |
| Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic Rhinitis (NCT01382654) | Merck Sharp & Dohme LLC | 2006-09-01 |
| Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002) (NCT01324440) | Merck Sharp & Dohme LLC | 2006-09-01 |
| PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278) (NCT00371761) | Merck Sharp & Dohme LLC | 2006-09-01 |
| Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED) (NCT00393523) | Merck Sharp & Dohme LLC | 2006-09-01 |
| Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED) (NCT00384293) | Merck Sharp & Dohme LLC | 2006-09-01 |
| Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371) (NCT00381017) | Merck Sharp & Dohme LLC | 2006-09-01 |
| MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED) (NCT00372060) | Merck Sharp & Dohme LLC | 2006-08-21 |
| A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005) (NCT02004886) | Merck Sharp & Dohme LLC | 2006-08-11 |
| A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002) (NCT00635778) | Merck Sharp & Dohme LLC | 2006-08-07 |
| Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea (NCT00392574) | Merck Sharp & Dohme LLC | 2006-08-01 |
| A Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methorexate (Extension Part)(Study P05645)(COMPLETED) (NCT00732875) | Merck Sharp & Dohme LLC | 2006-08-01 |
| Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427) (NCT00724854) | Merck Sharp & Dohme LLC | 2006-08-01 |
| A Study to Evaluate the Efficacy of MK0719 in the Prevention of Postoperative Dental Pain (0719-002) (NCT00424424) | Merck Sharp & Dohme LLC | 2006-08-01 |
| Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) (NCT00871663) | Merck Sharp & Dohme LLC | 2006-08-01 |
| Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295) (NCT00394914) | Merck Sharp & Dohme LLC | 2006-08-01 |
| A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT) (NCT00369941) | Merck Sharp & Dohme LLC | 2006-08-01 |
| A Study to Assess the Bioequivalence of Famotidine Chewable Tablets and Film-Coated Tablets (0208-144) (NCT00945750) | Merck Sharp & Dohme LLC | 2006-08-01 |
| Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628) (NCT00686699) | Merck Sharp & Dohme LLC | 2006-07-10 |
| Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054) (NCT00378833) | Merck Sharp & Dohme LLC | 2006-07-01 |
| A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED) (NCT00565006) | Merck Sharp & Dohme LLC | 2006-07-01 |
| Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease (NCT00357279) | Merck Sharp & Dohme LLC | 2006-07-01 |
| Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED) (NCT00376584) | Merck Sharp & Dohme LLC | 2006-07-01 |
| Ezetrol Post-Marketing Study (NCT00753883) | Merck Sharp & Dohme LLC | 2006-07-01 |
| A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048) (NCT00373490) | Merck Sharp & Dohme LLC | 2006-07-01 |
| A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED) (NCT00565292) | Merck Sharp & Dohme LLC | 2006-07-01 |
| V501 Efficacy Study in Women Aged 18 to 26 (V501-027) (NCT00378560) | Merck Sharp & Dohme LLC | 2006-06-12 |
| Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052) (NCT00350779) | Merck Sharp & Dohme LLC | 2006-06-12 |
| The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) (NCT00392171) | Merck Sharp & Dohme LLC | 2006-06-09 |
| Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (NCT00337610) | Merck Sharp & Dohme LLC | 2006-06-01 |
| A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612) (NCT00687401) | Merck Sharp & Dohme LLC | 2006-06-01 |
| A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006) (NCT00290550) | Merck Sharp & Dohme LLC | 2006-06-01 |
| MK0859 Dose-Ranging Study (0859-003) (NCT00325455) | Merck Sharp & Dohme LLC | 2006-06-01 |
| Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801) (NCT00541775) | Merck Sharp & Dohme LLC | 2006-06-01 |
| Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005) (NCT00543959) | Merck Sharp & Dohme LLC | 2006-06-01 |
| PegIntron Injection Surveillance Plan (Study P04123) (NCT00723931) | Merck Sharp & Dohme LLC | 2006-06-01 |
| Hyzaar Asia HEAALTH (0954A-950) (NCT00354991) | Merck Sharp & Dohme LLC | 2006-06-01 |
| Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED) (NCT00727077) | Merck Sharp & Dohme LLC | 2006-06-01 |
| A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153) (NCT00546286) | Merck Sharp & Dohme LLC | 2006-05-31 |
| A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528) (NCT00687362) | Merck Sharp & Dohme LLC | 2006-05-30 |
| Open, Pharmacokinetic Study of Caspofungin in Neonates and Infants (0991-058) (NCT00330395) | Merck Sharp & Dohme LLC | 2006-05-01 |
| Biomarkers of Prednisolone Treatment (P05888) (NCT00971724) | Merck Sharp & Dohme LLC | 2006-05-01 |
| Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563) (NCT00358670) | Merck Sharp & Dohme LLC | 2006-05-01 |
| MK0354 Clinical Efficacy and Tolerability Study (0354-004) (NCT00337415) | Merck Sharp & Dohme LLC | 2006-05-01 |
| Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED) (NCT00337428) | Merck Sharp & Dohme LLC | 2006-05-01 |
| Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056) (NCT00322361) | Merck Sharp & Dohme LLC | 2006-05-01 |
| Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739) (NCT00704808) | Merck Sharp & Dohme LLC | 2006-05-01 |
| Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED) (NCT00378599) | Merck Sharp & Dohme LLC | 2006-05-01 |